A Study to Evaluate the Effect of a Topical Retinol on Epigenetic Changes and Expression of Certain Genes in the Skin Using Non-invasive Measurements

Inclusion Criteria:

1. Has clinically determined moderate photodamage (defined as a score of 4 - 6 on a 0- 9-point scale) on the face at Visit 1.

2. Is able to read, write, speak, and understand English.

3. Generally in good health.

4. Intends to complete the study and is willing and able to follow all studyinstructions.

Exclusion Criteria:

1. Has known allergies or negative reactions to common topical skincare products,adhesives, latex, or ingredients in the study products.

2. Has clinically active bacterial, fungi, or viral skin infection or has frequent skininfections.

3. Presents with a skin condition that may increase risk to the subject, influencestudy results, or interfere with study evaluations (e.g. acne, psoriasis, eczema,atopic dermatitis, cutaneous xerosis, erythema, active skin cancer, tattoos,scarring, scratches/broken skin, sunburn, excessive hair growth, or very uneven skintone) as determined by the principal investigator (PI).

4. Has self-perceived sensitive skin.

5. Is a regular (occasional to daily) smoker of cigarettes or user of electroniccigarettes (vaping pens).

6. Is a regular (occasional or frequent) user of tanning beds and/or self-tanningproducts.

7. Has had a surgical or aesthetic procedure in the last 3 months that can affectfacial wrinkles or facial pigmentation (e.g. botulinum toxin (Botox) injections,chemical peels, laser-based therapies to the face, or face lift surgery).

8. Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication.

9. Is taking a medication that could mask a negative reaction or influence studyresults, as determined by the PI.

10. Is self-reported to be breastfeeding, pregnant or planning to become pregnant duringthe study.

11. Has a history of or a current health/other condition/situation which may put theindividual at significant risk, influence the study results, or interferesignificantly with the individual's participation in the study.

12. Is currently participating in any other clinical study or has participated in anyproduct-use study within 30 days prior to the study visit.

13. Is an employee/contractor or immediate family member of the PI, study site, orSponsor.